Adrian Hargrave, CEO of SEEEN, explains how the new funds will accelerate customer growth Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksGlaxosmithkline Share News (GSK)

Share Price Information for Glaxosmithkline (GSK)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 1,646.00
Bid: 1,645.50
Ask: 1,646.00
Change: 31.00 (1.92%)
Spread: 0.50 (0.03%)
Open: 1,631.00
High: 1,646.50
Low: 1,630.50
Prev. Close: 1,615.00
GSK Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

LONDON MARKET MIDDAY: FTSE 100 rises as Lloyds brightens bank sector

Wed, 28th Apr 2021 12:05

(Alliance News) - London stocks sustained moderate gains on Wednesday morning, with banks helping to prop up the FTSE 100 ahead of the latest US interest rate decision after the European close.

As well as the US Federal Reserve's policy announcement due later, focus also is on results from New York-listed tech stocks Apple and Facebook.

The blue-chip FTSE 100 index was up 21.89 points, or 0.3%, at 6,966.86 midday Wednesday. The mid-cap FTSE 250 index was up 99.83 points, or 0.5%, at 22,532.91. The AIM All-Share index was down 0.3% at 1,272.55.

The Cboe UK 100 index was up 0.5% at 693.21. The Cboe 250 was up 0.3% at 20,121.44, and the Cboe Small Companies up flat at 14519.66.

In mainland Europe, the CAC 40 in Paris was up 0.5%, while the DAX 30 in Frankfurt was up 0.4% on Wednesday.

Joshua Mahony, senior market analyst at IG, remarked that markets were posting "tentative gains" on Wednesday.

"Markets are waiting patiently for the latest update from the Federal Reserve today, although they could be disappointed. Despite a resurgence in jobs and inflation data, we are unlikely to see Powell lay the groundwork for any tapering in asset purchases today," said Mahony.

The Fed announces its latest monetary policy decision at 1900 BST, with a press conference with Chair Jerome Powell at 1930 BST.

The dollar climbed ahead of the US interest rate decision.

Sterling was quoted at USD1.3881 midday Wednesday, lower than USD1.3915 at the London equities close on Tuesday. The euro traded at USD1.2072, soft on USD1.2085 late Tuesday. Against the yen, the dollar was quoted at JPY108.92, up from JPY108.50.

However, stocks in New York were set for a largely lower open. The Dow Jones was called down 0.1% and the Nasdaq Composite was seen 0.2% lower, but the S&P 500 was set for a 0.1% rise.

Likely to weigh on the Nasdaq at the open are shares in Microsoft, trading 2.2% lower pre-market despite the software firm reporting quarterly profit growth. For its financial third quarter ended March 31, revenue was USD41.7 billion, up 19% from USD35.02 billion the year before and net income jumped 44% to USD15.46 billion from USD10.75 billion.

"One-off tax and currency advantages have boosted Microsoft's third quarter numbers, and as a result the market isn't being quite as welcoming of expectation-beating numbers as you might expect. That is the danger of trading on the kind of valuation Microsoft enjoys, 32.8 times next year's earnings, disappoint even a little and the market will be unforgiving," said Nicholas Hyett, equity analyst at Hargreaves Lansdown.

More positively, Alphabet shares jumped 5.1% pre-market on sharp growth in earnings and revenue for the first quarter of 2021, driven by a rise in online consumer activity and advertiser revenue. For the three months to the end of March, the Google parent posted net income of USD17.93 billion, more than doubled from USD6.84 billion the same period the year before.

Focus switches to the next raft of US tech earnings, with reports from iPhone maker Apple and social media behemoth Facebook after the New York market close.

In London, a strong first quarter showing from high street lender Lloyds was helping the boost other UK banks. NatWest shares rose 2.0% and Barclays was up 1.2%.

Lloyds topped the FTSE 100 at midday, shares up 4.4%, as profit shot up in the first quarter of 2021 in outgoing Chief Executive Antonio Horta-Osorio's last set of results at the bank.

Pretax profit for the three months to the end of March surged to GBP1.90 billion from just GBP74 million a year ago, aided by a net impairment credit of GBP323 million, versus a charge of GBP1.43 billion a year ago.

Given the "solid performance" in the first quarter of 2021, Lloyds enhanced its guidance for 2020. Its net interest margin is now expected to be in excess of 245 basis points, after posting 249 basis points for the first quarter, and operating costs to be reduced to GBP7.5 billion.

HSBC Wealth & Personal Banking head Charlie Nunn will become the new Lloyds CEO on August 16. Lloyds Chief Financial Officer William Chalmers will be interim-CEO after Horta-Osorio departs and before Nunn comes in.

Horta-Osorio is heading to Credit Suisse to be its new chair - joining at a rocky time for the Swiss bank after it last week swung to a first quarter loss due to the implosion of US hedge fund Archegos.

The FTSE 100 also was supported by advertising and marketing firm WPP, shares up 3.6% at midday. In the first quarter of 2021, revenue rose 1.8% annually to GBP2.90 billion. On a like-for-like basis, WPP's first quarter revenue was 6.3% higher.

At the bottom of the FTSE 100 was precious metals miner Fresnillo, down 3.1% after a slightly mixed first quarter.

Gold output in the first quarter of 2021 rose 16% annually to 228,193 ounces. This represented a 5.9% quarter-on-quarter hike from 215,581 ounces in the fourth quarter of 2020.

Total silver output, however, fell 4.5% annually to 12.6 million ounces from 13.2 million and 2.4% on a quarterly basis from 13.0 million.

Gold was quoted at USD1,767.66 an ounce on Wednesday, lower than USD1,780.50 on Tuesday. Brent oil was trading at USD66.43 a barrel, up from USD66.11 late Tuesday.

J Sainsbury fell 2.6% as the grocer was pulled to a full-year loss on virus-related costs.

In the year ended March 8, the London-based grocer's revenue rose 0.2% to GBP29.04 billion, from GBP28.99 billion. It swung to a pretax loss of GBP261 million from the prior year's GBP255 million profit.

Underlying pretax profit fell 39% to GBP356 million, topping consensus of GBP338 million as well as the company's own forecast of GBP330 million. Profit was hit by GBP485 million of direct Covid-19 costs, offsetting a strong sales performance excluding fuel. Fuel sales were hurt by reduced demand during lockdown and the impact of lower crude oil prices on the petrol sales price.

Reckitt Benckiser slipped 2.2% despite reporting like-for-like revenue growth in the first quarter, leaving its full-year guidance unchanged.

The Slough, Berkshire-based consumer health and hygiene products company's total net revenue for the first quarter of 2021 grew 4.1% on a like-for-like basis, though fell 1.1% on a reported basis. Demand for Lysol and Dettol continues to be strong, the company said, amid "ongoing, elevated demand" for its disinfection products overall.

Reporting at midday, pharmaceutical firm GlaxoSmithKline confirmed its earlier financial guidance for 2021 and said the spin-off of its consumer arm is on track for 2022. In the first quarter, sales totalled GBP7.4 billion, up 18% or up 15% at constant exchange rates.

Glaxo shares were up 1.3% following the announcement.

In the FTSE 250, Grafton Group jumped 9.7%. The Dublin-based building materials distributor and DIY retailer said its first quarter revenue rose by a third.

Grafton recorded revenue of GBP846.8 million between January 1 and April 18, an increase of 33% on the same period last year and an 8.3% rise compared to 2019. The revenue gains were driven by the Retailing segment, with revenue more than doubling from a year prior and up 70% from 2019.

Travis Perkins fell 8.3% after the builders' merchant completed the demerger of its DIY retailing business, with Wickes Group making its London Main Market debut. Wickes was trading at 270.70 pence per share, giving it a value just over GBP680 million.

The Northampton-based firm added it will implement a share consolidation to keep its stock price close to pre-demerger levels. The ratio for the share consolidation will depend on its stock price at the close of trading on Wednesday.

By Lucy Heming; lucyheming@alliancenews.com

Copyright 2021 Alliance News Limited. All Rights Reserved.

More News
30 Oct 2023 09:01

IN BRIEF: GSK says Jemperli meets endpoint in endometrial cancer trial

GSK PLC - Brentford, west London-based pharmaceutical maker - Jemperli, whose generic name is dostarlimab, meets endpoint of overall survival in phase III Ruby trial on adult patients with primary advanced or recurrent endometrial cancer. Jemperli, combined with standard-of-care chemotherapy, followed by dostarlimab, demonstrated a "statistically significant and clinically meaningful benefit" to the patients in the trial.

Read more
30 Oct 2023 07:06

GSK's Jemperli sees success in endometrial cancer trial

(Sharecast News) - GSK reported encouraging outcomes from part one of the 'RUBY' phase three trial evaluating the efficacy of 'Jemperli', or dostarlimab, with standard chemotherapy for treating adult patients with advanced or recurrent endometrial cancer on Monday.

Read more
26 Oct 2023 09:19

TOP NEWS: GSK subsidiary ViiV receives HIV drug approval in China

(Alliance News) - GSK PLC on Thursday said its subsidiary ViiV Healthcare has received marketing authorisation in China for its cabotegravir treatment, marketed as Vocabria.

Read more
26 Oct 2023 07:02

GSK HIV injection regimen gets approval in China

(Sharecast News) - GSK announced on Thursday that its majority-owned HIV specialist subsidiary ViiV has received approval from the National Medical Products Administration (NMPA) of China for an injection regimen.

Read more
25 Oct 2023 16:01

UK earnings, trading statements calendar - next 7 days

Thursday 26 October 
Bank of Ireland Group PLCTrading Statement
Bloomsbury Publishing PLCHalf Year Results
Botswana Diamonds PLCTrading Statement
C&C Group PLCHalf Year Results
e-Therapeutics PLCHalf Year Results
Financials Acquisition CorpTrading Statement
GCP Infrastructure Investments LtdTrading Statement
HarbourVest Global Private Equity LtdHalf Year Results
Hummingbird Resources PLCTrading Statement
Hunting PLCTrading Statement
Inchcape PLCTrading Statement
International Personal Finance PLCTrading Statement
PPHE Hotel Group LtdTrading Statement
Renishaw PLCTrading Statement
Standard Chartered PLCQ3 Results
Unilever PLCTrading Statement
WPP PLCTrading Statement
Friday 27 October 
International Consolidated Airlines Group SAQ3 Results
NatWest Group PLCQ3 Results
Monday 30 October 
Airtel Africa PLCHalf Year Results
Computacenter PLCTrading Statement
Glencore PLCTrading Statement
HSBC Holdings PLCQ3 Results
Lok'n Store Group PLCFull Year Results
Pearson PLCTrading Statement
Tuesday 31 October 
BP PLCQ3 Results
Coca-Cola HBC AGTrading Statement
Elementis PLCTrading Statement
essensys PLCFull Year Results
Georgia Capital PLCQ3 Results
Grit Real Estate Income Group LtdFull Year Results
RHI Magnesita NVTrading Statement
Spectris PLCQ3 Results
TP ICAP Group PLCTrading Statement
UP Global Sourcing Holdings PLCFull Year Results
Wednesday 1 November 
Asos PLCFull Year Results
Aston Martin Lagonda Global Holdings PLCQ3 Results
Beximco Pharmaceuticals LtdFull Year Results
GSK PLCQ3 Results
Next PLCTrading Statement
Smurfit Kappa Group PLCTrading Statement
Weir Group PLCTrading Statement
  
Copyright 2023 Alliance News Ltd. All Rights Reserved.

Read more
25 Oct 2023 09:35

GSK says RSV jab shows promising response in adults aged 50 to 59

(Alliance News) - GSK PLC on Wednesday said a trial found its respiratory syncytial virus vaccine Arexy delivered an immune response in adults aged 50 to 59.

Read more
25 Oct 2023 07:27

GSK hails success in US RSV vaccine trial

(Sharecast News) - Pharma giant GSK has announced positive preliminary results from a trial of its Arexvy vaccine to treatment respiratory syncytial virus (RSV) disease for a younger patient population in the US.

Read more
16 Oct 2023 08:09

TOP NEWS: GSK receives positive EU opinion on Jemperli for cancer

(Alliance News) - GSK PLC on Monday said its monoclonal antibody Jemperli is closer to becoming the first new frontline treatment option in the EU in decades for a certain form of endometrial cancer.

Read more
16 Oct 2023 07:44

LONDON BRIEFING: Hipgnosis pulls interim dividend on lower royalties

(Alliance News) - The FTSE 100 is likely to open higher on Monday, benefitting from higher oil and gas prices, while fears of escalating regional conflict in the Middle East damp risk sentiment elsewhere.

Read more
16 Oct 2023 07:16

GSK nears green light for Jemperli usage in Europe

(Sharecast News) - Pharma giant GSK has announced that European experts recommended the approval of its Jerperli drug for the treatment of a specific type of endometrial cancer - paving the way for marketing authorisation by the continent's regulatory body.

Read more
11 Oct 2023 11:51

GSK settles California Zantac lawsuit

(Sharecast News) - GSK has agreed to settle another lawsuit concerning its discontinued heartburn treatment Zantac, the drugs giant confirmed on Wednesday.

Read more
11 Oct 2023 09:17

LONDON BROKER RATINGS: JPMorgan raises Croda; Berenberg cuts Atalaya

(Alliance News) - The following London-listed shares received analyst recommendations Wednesday morning:

Read more
11 Oct 2023 08:51

LONDON MARKET OPEN: FTSE 100 higher; Travis Perkins warns on profit

(Alliance News) - Stock prices in London opened largely higher on Wednesday as market mood remained resilient, despite the continuing conflict in the Middle East, amid a softening of rhetoric from the US central bank.

Read more
11 Oct 2023 08:36

TOP NEWS: GSK reaches settlement for Zantac litigation in California

(Alliance News) - GSK PLC on Wednesday said that it has reached a confidential settlement in the Cantlay/Harper case, which alleged that the firm's heartburn medication can cause cancer.

Read more
11 Oct 2023 07:47

LONDON BRIEFING: Stocks lower; GSK settles Zantac case in California

(Alliance News) - Stocks in London are set to open lower on Wednesday as investor looked ahead to the release of the US Federal Reserve's September meeting minutes later in the day.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.